Investor Stock List
Ranked #2,301 of 8,699 institutional investors

Fcpm III Services B.v.

Naarden, P7

$1.04B
US stock portfolio at live prices · today +$20.9M (+2.05%)
Market closed. Prices as of Nov 20, 7:11 AM ET
Value at quarter end (Q3 2026)
$1.06B
Change from Q2 2026
+$310.3M (+41.35%)
Positions
10 · 4 new, 0 sold out
Filed
Nov 16, 2026

Not counted in the ranking: none$308M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
BRVE 40.4%KRSA 7.47%VOR 6.06%DYN 5.53%AURA 3.52%
StockSharesValue, live% of portfoliovs Q2 2026
BRVE Braveheart Bio, Inc.21,826,024$421M40.4%New
KRSA Korsana Biosciences, Inc.2,192,155$77.7M7.47%New
VOR Vor Biopharma Inc.3,405,279$63.1M6.06%Reduced −17%
DYN Dyne Therapeutics, Inc.3,586,796$57.5M5.53%Reduced −7%
AURA Aura Biosciences, Inc.5,248,841$36.6M3.52%Added +29%
REPL Replimune Group, Inc.1,720,500$33.1M3.18%Reduced −39%
MPLT MapLight Therapeutics, Inc.4,428,328$28.4M2.73%Added +37%
BCYC Bicycle Therapeutics plc3,468,430$10.6M1.02%Unchanged
TARS Tarsus Pharmaceuticals, Inc.64,087$5.0M0.48%New
LSTA Lisata Therapeutics, Inc.297,478$271K<0.1%New